Simple Summary: Protein structure prediction using computer algorithms has long been a challenge; however, the recent introduction of algorithms like AlphaFold2 and ESMFold to predict protein structure has raised the hope for in silico drug discovery, a long sought-after breakthrough. Since the release of these algorithms, it has not been realized whether these algorithms apply if the structure is already reported to be available to the algorithms. Still, the confidence in the predicted structure varies from very low to very high, which is an observation that is unrelated to any physicochemical or biological property of the protein. Any amino acid chain sequence change fails to predict the structure, limiting the utility of these algorithms to an academic exercise. Still, researchers continue to search for the utility of the confidence scores and, despite failing, continue to suggest possible applications, resulting from the logical belief that if the confidence scores are different and reproducible, this must relate to the protein structure. To end this misconception, we predicted the structures of 204 FDA-approved therapeutic proteins, with a wishful thought that the confidence scores, if correlated on this large database, can assist in rank-ordering these proteins for their possible batch-to-batch variability, which could help to reduce testing when these molecules are developed as biosimilars. We also studied modified structures that were not predicted since no reference structure was available for the algorithms to function. This conclusion applies to the two tested algorithms, which showed comparable and proportional confidence intervals. This conclusion is controversial but deserves the attention of researchers who continue to hope to find any drug discovery utility for these algorithms. The three-dimensional protein structure is pivotal in comprehending biological phenomena. It directly governs protein function and hence aids in drug discovery. The development of protein prediction algorithms, such as AlphaFold2, ESMFold, and trRosetta, has given much hope in expediting protein-based therapeutic discovery. Though no study has reported a conclusive application of these algorithms, the efforts continue with much optimism. We intended to test the application of these algorithms in rank-ordering therapeutic proteins for their instability during the pre-translational modification stages, as may be predicted according to the confidence of the structure predicted by these algorithms. The selected molecules were based on a harmonized category of licensed therapeutic proteins; out of the 204 licensed products, 188 that were not conjugated were chosen for analysis, resulting in a lack of correlation between the confidence scores and structural or protein properties. It is crucial to note here that the predictive accuracy of these algorithms is contingent upon the presence of the known structure of the protein in the accessible database. Consequently, our conclusion emphasizes that these algorithms primarily replicate information derived from existing structures. While our findings caution against relying on these algorithms for drug discovery purposes, we acknowledge the need for a nuanced interpretation. Considering their limitations and recognizing that their utility may be constrained to scenarios where known structures are available is important. Hence, caution is advised when applying these algorithms to characterize various attributes of therapeutic proteins without the support of adequate structural information. It is worth noting that the two main algorithms, AlfphaFold2 and ESMFold, also showed a 72% correlation in their scores, pointing to similar limitations. While much progress has been made in computational sciences, the Levinthal paradox remains unsolved. [ABSTRACT FROM AUTHOR]